The New England Journal of Medicine earlier this month.“The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir).
We are concerned that the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design," Gilead said in a statement on Friday.The WHO trial was an open-label trial, in which 11,266 adults from 30 were randomized, with 2,750 allocated remdesivir, 954 hydroxychloroquine, 1,411 lopinavir, 651 interferon and lopinavir, 1,412 only Interferon, and 4,088 no study.
Read more on livemint.com